Lineage Cell Therapeutics, Inc. (LCTX)

1.11 -4.31% (-0.05)

Over 3Y: -17.8%

2026-08-28
Style
Area Line Line with markersneeds a shorter window Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

0.5 1 1.5 2
2023 2024 2025 2026

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 3.7M Q3 '25 — Operating Cash Flow: -3.6M Q3 '25 — Free Cash Flow: -3.6M Q3 '25 — Net Income: -29.8M Q4 '25 — Revenue: 6.6M Q4 '25 — Operating Cash Flow: -4.9M Q4 '25 — Free Cash Flow: -5.3M Q4 '25 — Net Income: 851K Q1 '26 — Revenue: 1.7M Q1 '26 — Operating Cash Flow: -8.1M Q1 '26 — Free Cash Flow: -8.1M Q1 '26 — Net Income: -4.8M Q2 '26 — Revenue: 1.1M Q2 '26 — Operating Cash Flow: -7.2M Q2 '26 — Free Cash Flow: -7.4M Q2 '26 — Net Income: 1.5M -24M -16M -8M 0 8M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 38.8%
OE margin -225.2%
Oper. margin -205.2%
ROIC -209.3%
Accruals -7.9%
EBITDA margin -199.6%
FCF margin -186.4%
OCF margin -182.0%
Profit margin -246.6%
ROA -30.4%
ROCE -27.3%
ROE -53.0%
Gross margin —
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

2.1
RPO / sales 0.13×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA —
Interest cover -3356.2×
Cash / Debt 1058.9×
Debt / Eq 0.00079×
Debt payback 0.0 yr
Quick ratio 6.6×
Cash runway 2.1 yr
F-score 3.9 pts
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.1
Sales CAGR 4Y +35.3%
Sales/sh Y/Y +4.3%
Sales Q/Q -61.3%
Shares change +15.0%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.